Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, Tianjin, China.
Tianjin Neurosurgery Institute, Tianjin Key Laboratory of Cerebral Vessels and Neural Degeneration, Tianjin Huanhu Hospital, Tianjin, China.
Bull Exp Biol Med. 2022 Mar;172(5):543-548. doi: 10.1007/s10517-022-05429-y. Epub 2022 Mar 29.
We studied diagnostic and treatment values of the blood levels of platelet activation markers PNA, PMA, PLyA, PAC-1, and CD62P in 30 patients with acute ischemic stroke (median NIHSS score 4 (2; 6)) before and after treatment as well as in comparison with the control group. The levels of these markers were measured by flow cytometry. In patients with acute ischemic stroke, the levels of PLyA, PAC-1, and CD62P were significantly increased in comparison with the controls; therapy significantly reduced the levels of PAC-1, CD62P, and PMA in patients with acute ischemic stroke. The areas under the ROC curve differentiating acute ischemic stroke from healthy controls for PAC-1, CD62P, and PLyA were 0.694, 0.862, and 0.760, respectively. Our findings suggest that the levels of PLyA, PAC-1, and CD62P can be potential noninvasive biomarkers of acute ischemic stroke.
我们研究了血小板活化标志物 PNA、PMA、PLyA、PAC-1 和 CD62P 的血液水平在 30 例急性缺血性脑卒中患者（NIHSS 评分中位数 4（2；6））治疗前后的诊断和治疗价值，并与对照组进行了比较。这些标志物的水平通过流式细胞术进行测量。与对照组相比，急性缺血性脑卒中患者的 PLyA、PAC-1 和 CD62P 水平显著升高；治疗后急性缺血性脑卒中患者的 PAC-1、CD62P 和 PMA 水平显著降低。区分急性缺血性脑卒中与健康对照组的 PAC-1、CD62P 和 PLyA 的 ROC 曲线下面积分别为 0.694、0.862 和 0.760。我们的研究结果表明，PLyA、PAC-1 和 CD62P 的水平可能是急性缺血性脑卒中的潜在非侵入性生物标志物。
